Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report released on Wednesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Down 1.8 %

NASDAQ CPIX opened at $1.61 on Wednesday. The business has a fifty day moving average price of $1.85 and a 200 day moving average price of $1.88. Cumberland Pharmaceuticals has a one year low of $1.43 and a one year high of $2.36. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28. The company has a market cap of $22.83 million, a P/E ratio of -3.66 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $9.35 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently bought a new position in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp bought a new stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned approximately 0.52% of Cumberland Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.